



Veracyte Announces New Data To Be Presented at SITC 2021 Will Highlight Company's Immuno-Oncology Capabilities

November 2, 2021

Brightplex technology, acquired from HaliuDx, is designed to help drug developers understand and leverage the tumor micro-environment

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Nov. 2, 2021-- [Veracyte, Inc.](#) (Nasdaq: VCYT) today announced that three abstracts highlighting the company's immuno-oncology offerings for biopharmaceutical researchers will be presented at the Society for Immunotherapy of Cancer's (SITC) 36th Annual Meeting, taking place in Washington, DC and virtually, November 10-14, 2021.

"It is exciting to have the opportunity to present new data on our Brightplex assays and be able to provide to clinical researchers innovative solutions designed to help them better understand the mechanism of action for therapeutics," said Corinne Danan, Veracyte's general manager, Biopharma. "This is especially important in the immuno-oncology field where the micro-environment of the tumor plays a key role in cancer progression and response to therapy."

Veracyte acquired the novel Brightplex technology – which combines information from multiplex immunohistochemistry (IHC) and advanced digital pathology analysis to provide a comprehensive picture of the tumor micro-environment – through its acquisition of HaliuDx in August 2021.

The following posters will be presented at the SITC meeting:

Poster Title: "Assessment of the spatial distribution of B cells subpopulations in the tumor microenvironment and tertiary lymphoid structures by Brightplex®, a sequential chromogenic multiplex assay"

Abstract number: 57

Session Date/Time: Nov. 12, 7:00 a.m. – 8:00 p.m. ET (on-site) and Nov. 12, 7:00 a.m. ET (ePoster)

Poster Title: "Assessment of the spatial distribution of CD4+ T cells subpopulations in the tumor microenvironment by Brightplex®, a sequential chromogenic multiplex assay"

Abstract number: 41

Session Date/Time: Nov. 12, 7:00 a.m. – 8:00 p.m. ET (on-site) and Nov. 12, 7:00 a.m. ET (ePoster)

Poster Title: "Spatial distribution of infiltrating T lymphocytes with Immunoscore® CR T Cells Exhaustion test helps stratification of NSCLC patients treated with PD1/L1 inhibitors in the PIONeR project"

Abstract number: 460

Session Date/Time: Nov. 13, 7:00 a.m. – 8:00 p.m. ET (on-site) and Nov. 12, 7:00 a.m. ET (ePoster)

About Veracyte

Veracyte (Nasdaq: VCYT) is a global diagnostics company that improves patient care by providing answers to clinical questions, informing diagnosis and treatment decisions throughout the patient journey in cancer and other diseases. The company's growing menu of diagnostic tests leverages advances in genomic science and technology, enabling patients to avoid risky, costly diagnostic procedures and quicken time to appropriate treatment. The company's tests in lung cancer, prostate cancer, breast cancer, thyroid cancer, bladder cancer, colon cancer, and idiopathic pulmonary fibrosis are available to patients and its renal cancer and lymphoma subtyping tests are in development, the latter as a companion diagnostic. With Veracyte's exclusive global license to a best-in-class diagnostics instrument platform, the company is positioned to deliver its genomic tests to patients worldwide. Veracyte is based in South San Francisco, California. For more information, please visit www.veracyte.com and follow the company on Twitter (@veracyte).

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements, including, but not limited to, our statements related to our plans, objectives, expectations (financial and otherwise) or intentions with respect to Brightplex technology. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "expect," "believe," "should," "suggest," "may," "will" "prospective" and similar references to future periods. Actual results may differ materially from those projected or suggested in any forward-looking statements. Examples of forward-looking statements include, among others, statements regarding Veracyte's belief that its Brightplex technology can help clinical researchers to design more effective immunotherapies in cancer treatment. Additional factors that may impact these forward-looking statements can be found under the caption "Risk Factors" in our Annual Report on Form 10-K filed with the SEC on February 22, 2021 and our subsequent quarterly reports on Form 10-Q. A copy of these documents can be found at the Investors section of our website at www.veracyte.com. These forward-looking statements speak only as of the date hereof and, except as required by law, Veracyte specifically disclaims any obligation to update these forward-looking statements or reasons why actual results might differ, whether as a result of new information, future events or otherwise.

Veracyte, the Veracyte logo, HaliuDx, Brightplex, Decipher, Decipher GRID, Afirma, Percepta, Envisia, Prosigna, Lymphmark, "Know by Design" and "More about You" are registered trademarks of Veracyte, Inc. and its affiliates in the U.S. and selected countries. nCounter is the registered trademark of NanoString Technologies, Inc. in the U.S. and selected countries, and used by Veracyte under license. Immunoscore is the registered trademark of InSerm in the U.S. and selected countries, and is used by HaliuDx under license.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20211102005538/en/): <https://www.businesswire.com/news/home/20211102005538/en/>

Investor and Media Contact:

Tracy Morris
Vice President of Corporate Communications
& Investor Relations
tracy.morris@veracyte.com

650-380-4413

Source: Veracyte, Inc.